AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at ...
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market ...
Eli Lilly (LLY) and InnoCare Pharma agreed to collaborate on developing new medicines targeting up to five targets, InnoCare said Thursday. Under the agreement, InnoCare said it w ...
Eli Lilly's CEO says 700,000 seniors have begun taking GLP-1s since Medicare's July coverage launched, and most chose Lilly. What it means for LLY stock.
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Sign-ups for Medicare’s GLP-1 coverage plan keep expanding, and Eli Lilly is dominating the market with 70% share, the company’s CEO David Ricks said. | Sign-ups for Medicare’s GLP-1 coverage plan ...
China-based biopharmaceutical company InnoCare Pharma has signed a research and license agreement with Eli Lilly that could be valued at more than $3 billion. InnoCare, a specialist in cancer and ...
The pharmaceutical giant's new Houston-based facility will create 600 jobs, boosting life sciences in Generation Park.
The company continues to dominate the weight loss market.
The agreement provides up to $100 million upfront/near-term and up to ~$3.25 billion in milestones, plus single-digit tiered royalties, reflecting high optionality typical of early discovery ...
In 1876, Colonel Eli Lilly opened a small pharmaceutical company in Indianapolis with an idea that was, at the time, radical to some: make medicine that actually worked. He had witnessed soldiers die ...
When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results